NCT02565524

Brief Summary

Early onset schizophrenia "early dissociative disorder" is a rare disorder with a low incidence of approximately (1/5000 to 1/20000). Its link with autism spectrum disorders remains unknown although both are serious neurodevelopmental diseases. As part of the 2011-2013 Interregional hospital Clinical Research program, University Department of Child and Adolescent Psychiatry Pediatric Hospitals of CHU de Nice Lenval identified patients with a complex phenotype characterized by an early schizophrenia associated with autism spectrum disorders and developmental disabilities in mild to moderate. This phenotype could be a new syndrome. The goal of our project is to define the genetic causes of this phenotype. The technique of high throughput sequencing will be used to obtain the sequence of exomes of these patients and their families. This study will therefore be important to give an accurate diagnosis for patients and their families. Moreover, we believe that this project will identify new genes involved allowing a better understanding of the pathophysiology. Recent studies show the involvement of mutations in several genes (eg NRXN1 and UPF3B) in these different clinical phenotypes. However, the genetic basis of the childhood and early onset schizophrenia are much less well known than those of autism spectrum disorder

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
111

participants targeted

Target at P50-P75 for not_applicable schizophrenia

Timeline
Completed

Started May 2014

Longer than P75 for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 18, 2014

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

July 29, 2015

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 1, 2015

Completed
7.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2023

Completed
Last Updated

September 29, 2023

Status Verified

September 1, 2023

Enrollment Period

9 years

First QC Date

July 29, 2015

Last Update Submit

September 28, 2023

Conditions

Keywords

schizophreniaearly dissociative disordergenetic

Outcome Measures

Primary Outcomes (3)

  • characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing standard karyotype

    A standard karyotype at a resolution of 300 to 400 bands per haploid lot. It can diagnose numerical anomalies and certain structural abnormalities such as reciprocal translocations, inversions, deletions. A standard karyotype at a resolution of 300 to 400 bands per haploid lot is established initially. It can diagnose numerical anomalies and certain structural abnormalities such as reciprocal translocations, inversions, deletions Big. The pathological nature of these mutations will be stutied on the gene function and reaches its pattern of expression.

    inclusion visit

  • characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing search CGG

    A search of the CGG expansion hypermethylated in the 5 'UTR of the FMR1 gene mutation that causes Fragile X syndrome.

    inclusion visit

  • characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing whole exome sequencing

    Whole Exome Sequencing on trio (mother, father and child); This technology has demonstrated its power in recent years to determine the genetic causes of many rare diseases (Ropers, HH., 2012).

    inclusion visit

Secondary Outcomes (6)

  • Intensity of positive symptoms of schizophrenia

    inclusion visit

  • Co-morbid psychiatric diagnosis

    inclusion visit

  • Evaluation of executive and attentional by the verbal fluency test

    inclusion visit

  • Clinical evaluation of autistic symptoms

    inclusion visit

  • Neurocognitive profile

    inclusion visit

  • +1 more secondary outcomes

Study Arms (1)

genetic and phenotypic profile

EXPERIMENTAL

blood sample, clinical and neurocognitive assessment

Other: genetic and phenotypic profile

Interventions

Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood

genetic and phenotypic profile

Eligibility Criteria

Age7 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Of the child:
  • ≥ 7 years, \<18 (below 7 years the diagnosis of schizophrenia is not possible)
  • Schizophrenia Diagnosis done using the diagnostic tool Kiddie sads
  • Autism Diagnosis done using the diagnostic scale Autism Diagnostic interview (ADI-R)
  • Intelligence quotient (IQ) ≥ 50 at Wechsler Intelligence Scale for Children (WISC) IV abridged version
  • Clinical examination
  • Affiliation to social security
  • Obtaining the authorization of the holders of parental authority
  • Brothers and sisters:
  • Minor or Major
  • Similarly biological parents
  • Clinical examination
  • Affiliation to social security
  • Obtaining the authorization of the holders of parental authority for minors or informed consent for major
  • Parents:
  • +4 more criteria

You may not qualify if:

  • Of the child:
  • Children refusing to participate
  • Children without verbal language
  • Brothers and sisters:
  • Children refusing to participate
  • Adults protected by law
  • Parents:
  • Refusing to participate
  • Adults are protected by law

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondation Lenval

Nice, 06200, France

Location

Related Publications (1)

  • Fernandez A, Dor E, Maurin T, Laure G, Menard ML, Drozd M, Poinso F, Bardoni B, Askenazy F, Thummler S. Exploration and characterisation of the phenotypic and genetic profiles of patients with early onset schizophrenia associated with autism spectrum disorder and their first-degree relatives: a French multicentre case series study protocol (GenAuDiss). BMJ Open. 2018 Jul 5;8(7):e023330. doi: 10.1136/bmjopen-2018-023330.

MeSH Terms

Conditions

SchizophreniaDissociative Disorders

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Emmanuelle DOR, MD

    Fondation Lenval

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 29, 2015

First Posted

October 1, 2015

Study Start

May 18, 2014

Primary Completion

May 30, 2023

Study Completion

May 30, 2023

Last Updated

September 29, 2023

Record last verified: 2023-09

Locations